# ImmuniCell® in Patients With Advanced Cancers

> **NCT02459067** · PHASE2 · TERMINATED · sponsor: **TC Biopharm** · enrollment: 8 (actual)

## Conditions studied

- Malignant Melanoma
- Non-small Cell Lung Cancer
- Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** ImmuniCell®

## Key facts

- **NCT ID:** NCT02459067
- **Lead sponsor:** TC Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2018-11-27
- **Final completion:** 2018-11-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02459067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02459067, "ImmuniCell® in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02459067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*